Scholarlink

<p>Herein, a new library of triconjugates linked melatonin with the biological active cores of isatin and <i>N</i>-acylhydrazone were designed, synthetized, and their biological activity was evaluated in human colorectal cancer cells. All compounds were screened to determine the potential at a single dose of 100 µM against human colon adenocarcinoma SW480 cells, finding one compound <b>3e</b> which caused 100% inhibition and a certain grade of lethality at the conditions evaluated. In addition, the most active and soluble hybrids were further assessed using a five-dose scheme in the same colon cancer cells, and non-malignant human colon epithelial cells (NCM460) to establish the selective potential, finding that hybridized molecules <b>3e</b>, <b>3g</b>, and <b>3l</b> were more cytotoxic than parental compounds and 4-fold more selective than the reference drug (5-fluorouracil, 5-FU) which shows that molecular hybridization remains as a valuable tool to produce novel chemical entities that may result in advances in medicine. Lastly, according to a theoretical analysis on drug-like properties, pharmacokinetics, and toxicology, for the most promising hybrid <b>3e</b> would show a strong possibility of moving on to further preclinical research. Our results clearly demonstrated the effectiveness of melatonin/isatin/<i>N</i>-acylhydrazone triconjugates, with the 2-hydroxyphenylsubstituted compound in particular serving as a prototype drug for future investigations into innovative therapeutic treatments for colorectal cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of novel triconjugates fusing melatonin/isatin/N-acylhydrazone targeting colorectal cancer: design, synthesis, biological, and in silico ADME/Tox profiling

  • 期刊论文

  • 发表日期：

    2025年1月7日

查看全文
  • Sara M. Gutiérrez,
  • Wilson Cardona-Galeano,
  • Angie Herrera-Ramírez,
  • Andres F. Yepes

摘要

Herein, a new library of triconjugates linked melatonin with the biological active cores of isatin and N-acylhydrazone were designed, synthetized, and their biological activity was evaluated in human colorectal cancer cells. All compounds were screened to determine the potential at a single dose of 100 µM against human colon adenocarcinoma SW480 cells, finding one compound 3e which caused 100% inhibition and a certain grade of lethality at the conditions evaluated. In addition, the most active and soluble hybrids were further assessed using a five-dose scheme in the same colon cancer cells, and non-malignant human colon epithelial cells (NCM460) to establish the selective potential, finding that hybridized molecules 3e, 3g, and 3l were more cytotoxic than parental compounds and 4-fold more selective than the reference drug (5-fluorouracil, 5-FU) which shows that molecular hybridization remains as a valuable tool to produce novel chemical entities that may result in advances in medicine. Lastly, according to a theoretical analysis on drug-like properties, pharmacokinetics, and toxicology, for the most promising hybrid 3e would show a strong possibility of moving on to further preclinical research. Our results clearly demonstrated the effectiveness of melatonin/isatin/N-acylhydrazone triconjugates, with the 2-hydroxyphenylsubstituted compound in particular serving as a prototype drug for future investigations into innovative therapeutic treatments for colorectal cancer.